About regorafenib
Multikinase inhibitor
Used for
- Treats advanced colorectal cancer after other treatments
- Treats gastrointestinal stromal tumors after prior treatments
- Treats liver cancer after prior treatment
Usual adult dose
160 mg by mouth once daily for 21 days of each 28-day cycle; dose may be reduced for side effects.
Common side effects
- Hand-foot skin reaction
- Diarrhea
- Fatigue
- High blood pressure
Important warnings
- Can cause severe liver injury; liver tests are monitored.
- Bleeding, infection, and stomach or intestinal perforation can occur.
- May impair wound healing; it is generally stopped before planned surgery.
- Can cause fetal harm; effective contraception is needed during treatment.
Pregnancy
Can harm an unborn baby. Avoid during pregnancy; use effective contraception during treatment and for two months afterward.
Breastfeeding
Do not breastfeed during treatment and for two weeks after the final dose.
Interactions
- Strong CYP3A4 inducers, such as rifampin, may reduce regorafenib levels.
- Strong CYP3A4 inhibitors, such as ketoconazole, may increase regorafenib levels.
- May increase levels of CYP2C8 substrates, such as repaglinide.
- Warfarin and other blood thinners may increase bleeding risk.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.